Correction to: Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand

Bunchai Chongmelaxme¹ · Pochamana Phisalprapa² · Ratree Manthaisong^{3,4} · Piyameth Dilokthornsakul¹ · Nathorn Chaiyakunapruk^{1,4,5,6}

Published online: 13 December 2018
© Springer Nature Switzerland AG 2018

Correction to: PharmacoEconomics
<https://doi.org/10.1007/s40273-018-0736-0>

The title of the article should read:

Weight Reduction is Cost-Effective for the Treatment of
Non-alcoholic Fatty Liver Disease in Thailand.

The original article can be found online at <https://doi.org/10.1007/s40273-018-0736-0>.

✉ Piyameth Dilokthornsakul
piyamethd@gmail.com

✉ Nathorn Chaiyakunapruk
nathorn.chaiyakunapruk@monash.edu

¹ Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, 65000 Phitsanulok, Thailand

² Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

³ Clinical Pharmacy Research Unit, Department of Clinical Pharmacy, Faculty of Pharmacy, Mahasarakham University, Mahasarakham, Thailand

⁴ School of Pharmacy, Monash University Malaysia, Selangor, Malaysia

⁵ School of Pharmacy, University of Wisconsin, Wisconsin, MA, USA

⁶ Asian Centre for Evidence Synthesis in Population, Implementation and Clinical Outcomes (PICO), Health and Well-Being Cluster, Global Asia in the 21st Century (GA21) Platform, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia